The margenza market research report is one of a series of new reports that provides margenza market statistics, including the margenza industry global market size, regional shares, competitors with the margenza market share, detailed margenza market segments, market trends, and opportunities, and any further data you may need to thrive in the margenza industry. This margenza market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The growth in the forecast period can be attributed to increasing focus on personalized medicine, rising adoption of biosimilars, increasing preference for outpatient treatment, rising healthcare expenditure, and rising geriatric population. Major trends in the forecast period include technological advancements, innovative technology, advancements in drug development technologies, a shift toward combination therapies, and artificial intelligence for drug discovery.
The rising incidence of HER2-positive breast cancer is expected to drive the growth of the margenza market in the coming years. HER2-positive breast cancer is a form of breast cancer characterized by an overproduction of the HER2 protein on the surface of cancer cells. The increase in HER2-positive breast cancer cases is attributed to several factors, including advancements in screening technologies that allow for better detection, genetic and environmental factors, an aging population, and hormonal and reproductive influences that may heighten susceptibility to this particular subtype of cancer. Margenza is beneficial for treating HER2-positive breast cancer by targeting and blocking the HER2 protein, which helps slow or halt the growth of cancer cells that overproduce this protein. According to the National Institutes of Health (NIH), the incidence rate of HER2-positive breast cancer is expected to rise to 13-14 cases per 100,000 women by 2030. As a result, the growing number of HER2-positive breast cancer cases is expected to fuel the demand for margenza in clinical trials.
The increasing healthcare expenditure is also expected to significantly contribute to the growth of the margenza market. Healthcare expenditure refers to the total amount of money spent on medical services, treatments, and infrastructure, covering both public and private spending on healthcare systems, medical equipment, and pharmaceuticals. The rise in healthcare spending is driven by factors such as aging populations, advancements in medical technology, the increasing prevalence of chronic diseases, and the growing demand for high-quality healthcare services. Higher healthcare budgets facilitate greater investment in advanced treatments, including targeted therapies such as Margenza. As more resources are allocated to healthcare by governments, private insurers, and individuals, the affordability and availability of expensive cancer treatments improve. For example, according to the Centers for Medicare & Medicaid Services, U.S. healthcare spending increased by 4.1% in 2024, reaching a total of $4.5 trillion, or $13,493 per capita. This rising healthcare expenditure is expected to drive the growth of the margenza market.
In October 2024, TerSera Therapeutics, a U.S.-based pharmaceutical company, acquired the rights to the breast cancer drug Margenza (margetuximab) from MacroGenics for an undisclosed amount. This acquisition is part of TerSera’s strategy to expand its oncology portfolio and offer a new treatment option for patients with HER2-positive breast cancer. MacroGenics, a biotechnology company based in the U.S., specializes in developing antibody-based therapeutics for cancer treatment, including Margenza (margetuximab-cmkb). This acquisition highlights the growing interest and investment in treatments for HER2-positive breast cancer, further contributing to the expansion of the Margenza market.
The key company operating in the margenza market is MacroGenics Inc.
North America was the largest region in the margenza market in 2024. The regions covered in margenza report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the margenza market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Margenza (margetuximab-cmkb) is a monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2). It is approved for use in combination with chemotherapy to treat adult patients with metastatic HER2-positive breast cancer who have previously received two or more anti-HER2 regimens, with at least one being for metastatic disease.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary indications for margenza are breast cancer and gastric cancer. Breast cancer is a malignancy that originates in the cells of the breast, usually in the ducts or lobules, and can spread to other parts of the body if not detected and treated in time. Margenza is available in different formulations, including intravenous infusion and subcutaneous injection. It is distributed through various channels, such as hospitals, oncology clinics, and home healthcare services. The medication is used by a range of patients, including adults and geriatric populations.
The margenza market consists of sales of margenza (margetuximab) injection, combination therapies, and supportive care medications. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to increasing focus on personalized medicine, rising adoption of biosimilars, increasing preference for outpatient treatment, rising healthcare expenditure, and rising geriatric population. Major trends in the forecast period include technological advancements, innovative technology, advancements in drug development technologies, a shift toward combination therapies, and artificial intelligence for drug discovery.
The rising incidence of HER2-positive breast cancer is expected to drive the growth of the margenza market in the coming years. HER2-positive breast cancer is a form of breast cancer characterized by an overproduction of the HER2 protein on the surface of cancer cells. The increase in HER2-positive breast cancer cases is attributed to several factors, including advancements in screening technologies that allow for better detection, genetic and environmental factors, an aging population, and hormonal and reproductive influences that may heighten susceptibility to this particular subtype of cancer. Margenza is beneficial for treating HER2-positive breast cancer by targeting and blocking the HER2 protein, which helps slow or halt the growth of cancer cells that overproduce this protein. According to the National Institutes of Health (NIH), the incidence rate of HER2-positive breast cancer is expected to rise to 13-14 cases per 100,000 women by 2030. As a result, the growing number of HER2-positive breast cancer cases is expected to fuel the demand for margenza in clinical trials.
The increasing healthcare expenditure is also expected to significantly contribute to the growth of the margenza market. Healthcare expenditure refers to the total amount of money spent on medical services, treatments, and infrastructure, covering both public and private spending on healthcare systems, medical equipment, and pharmaceuticals. The rise in healthcare spending is driven by factors such as aging populations, advancements in medical technology, the increasing prevalence of chronic diseases, and the growing demand for high-quality healthcare services. Higher healthcare budgets facilitate greater investment in advanced treatments, including targeted therapies such as Margenza. As more resources are allocated to healthcare by governments, private insurers, and individuals, the affordability and availability of expensive cancer treatments improve. For example, according to the Centers for Medicare & Medicaid Services, U.S. healthcare spending increased by 4.1% in 2024, reaching a total of $4.5 trillion, or $13,493 per capita. This rising healthcare expenditure is expected to drive the growth of the margenza market.
In October 2024, TerSera Therapeutics, a U.S.-based pharmaceutical company, acquired the rights to the breast cancer drug Margenza (margetuximab) from MacroGenics for an undisclosed amount. This acquisition is part of TerSera’s strategy to expand its oncology portfolio and offer a new treatment option for patients with HER2-positive breast cancer. MacroGenics, a biotechnology company based in the U.S., specializes in developing antibody-based therapeutics for cancer treatment, including Margenza (margetuximab-cmkb). This acquisition highlights the growing interest and investment in treatments for HER2-positive breast cancer, further contributing to the expansion of the Margenza market.
The key company operating in the margenza market is MacroGenics Inc.
North America was the largest region in the margenza market in 2024. The regions covered in margenza report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the margenza market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Margenza (margetuximab-cmkb) is a monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2). It is approved for use in combination with chemotherapy to treat adult patients with metastatic HER2-positive breast cancer who have previously received two or more anti-HER2 regimens, with at least one being for metastatic disease.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary indications for margenza are breast cancer and gastric cancer. Breast cancer is a malignancy that originates in the cells of the breast, usually in the ducts or lobules, and can spread to other parts of the body if not detected and treated in time. Margenza is available in different formulations, including intravenous infusion and subcutaneous injection. It is distributed through various channels, such as hospitals, oncology clinics, and home healthcare services. The medication is used by a range of patients, including adults and geriatric populations.
The margenza market consists of sales of margenza (margetuximab) injection, combination therapies, and supportive care medications. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Margenza Market Characteristics4. Margenza Market Trends And Strategies5. Margenza Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Margenza Pricing Analysis & Forecasts30. Global Margenza Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Margenza Market32. Recent Developments In The Margenza Market
3. Margenza Market Biologic Drug Characteristics
6. Global Margenza Growth Analysis And Strategic Analysis Framework
8. Margenza Market Segmentation
9. Global Margenza Epidemiology Of Clinical Indications
10. Margenza Market Regional And Country Analysis
11. Asia-Pacific Margenza Market
12. China Margenza Market
13. India Margenza Market
14. Japan Margenza Market
15. Australia Margenza Market
16. South Korea Margenza Market
17. Western Europe Margenza Market
18. UK Margenza Market
19. Germany Margenza Market
20. France Margenza Market
21. Eastern Europe Margenza Market
22. North America Margenza Market
23. USA Margenza Market
24. Canada Margenza Market
25. South America Margenza Market
26. Middle East Margenza Market
27. Africa Margenza Market
28. Margenza Market Competitive Landscape And Company Profiles
29. Global Margenza Market Pipeline Analysis
33. Margenza Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Margenza Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on margenza market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for margenza ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The margenza market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: Breast Cancer; Gastric Cancer2) By Formulation: Intravenous Infusion; Subcutaneous Injection
3) By Distribution Channel: Hospitals; Oncology Clinics; Home Healthcare Services;
4) By End User: Adult Patients; Geriatric Patients
Key Companies Profiled: MacroGenics Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- MacroGenics Inc.
